Cellebrite DI Ltd. (NASDAQ:CLBT) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have received a consensus recommendation of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $16.70.

A number of equities research analysts have weighed in on CLBT shares. Weiss Ratings cut shares of Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 27th. JPMorgan Chase & Co. lowered their price objective on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a research report on Friday, August 14th. Lake Street Capital dropped their target price on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 14th. DA Davidson cut their target price on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Finally, Needham & Company LLC cut their target price on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a research report on Friday, August 14th.

Cellebrite DI Price Performance

NASDAQ CLBT opened at $11.45 on Monday. The firm’s 50-day moving average is $14.06 and its two-hundred day moving average is $13.68. Cellebrite DI has a 12 month low of $9.58 and a 12 month high of $19.98. The stock has a market capitalization of $2.86 billion, a P/E ratio of 52.05, a PEG ratio of 1.83 and a beta of 1.15.

Insider Transactions at Cellebrite DI

In related news, CMO David Gee sold 4,323 shares of the firm’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $11.36, for a total transaction of $49,109.28. Following the completion of the transaction, the chief marketing officer directly owned 135,281 shares in the company, valued at $1,536,792.16. This trade represents a 3.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas E. Hogan sold 25,299 shares of Cellebrite DI stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $11.29, for a total value of $285,625.71. Following the completion of the transaction, the insider directly owned 765,249 shares of the company’s stock, valued at approximately $8,639,661.21. This represents a 3.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 329,658 shares of company stock valued at $4,970,967. Corporate insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Cooper Creek Partners Management LLC purchased a new stake in Cellebrite DI during the 3rd quarter worth approximately $55,999,000. Capital International Investors acquired a new stake in Cellebrite DI during the 4th quarter worth approximately $41,073,000. Invesco Ltd. boosted its position in Cellebrite DI by 58.6% in the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock valued at $103,030,000 after buying an additional 2,054,644 shares during the period. California State Teachers Retirement System increased its position in shares of Cellebrite DI by 1,595.2% during the second quarter. California State Teachers Retirement System now owns 1,972,752 shares of the company’s stock worth $28,802,000 after acquiring an additional 1,856,378 shares during the period. Finally, Weiss Asset Management LP increased its position in shares of Cellebrite DI by 3,485.3% during the first quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock worth $26,180,000 after acquiring an additional 1,846,851 shares during the period. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.